Oncology and Hematology News and Journal Articles

New Treatment Options and Management Considerations in Borderline Resectable Pancreatic Cancer

Zeljka Jutric, MD, and Laleh G. Melstrom, MD, MS
Cancer In this article we will discuss the definitions of resectability, describe the current diagnostic tests for pancreatic cancer, and review strategies for maximizing treatment outcomes in patients with resectable pancreatic cancer.

Recent Content

Bevacizumab Fails to Improve Survival in Resected High-Risk Melanoma

News | June 25, 2017 | Melanoma

By Leah Lawrence

Treatment with single-agent bevacizumab resulted in an improved disease-free interval in patients with resected melanoma, but no increase in overall survival compared with observation.

Tumor Location Prognostic for Outcomes Even After Multivariable Adjustment

News | June 24, 2017 | Colorectal Cancer, ASCO

By Leah Lawrence

The primary tumor location was an independent prognostic marker in patients with RAS wild-type metastatic colorectal cancer after multivariable adjustment.

$On January 19, the US Food and Drug Administration (FDA) approved the oral Bruton tyrosine kinase inhibitor ibrutinib for the treatment of patients with relapsed or refractory marginal zone lymphoma who require systemic therapy and have had at least one prior anti-CD20 therapy. <a href="http://www.cancernetwork.com/news/fda-approved-ibrutinib-relapsed-refractory-marginal-zone-lymphoma" target="_blank">Read More</a>$

FDA Cancer Drug Approvals in 2017

Cancer Network Editors

June 23, 2017

By Cancer Network Editors

This slide show highlights some of this year’s FDA approvals of cancer treatments, including new therapies and indications for breast cancer, lung cancer, and various blood cancers, as well as the first approval based not on disease site but rather by a tumor marker.

Midostaurin Improves Survival in FLT3-Mutant AML

News | June 23, 2017 | Leukemia & Lymphoma, Hematologic Malignancies

By Dave Levitan

Adding midostaurin to chemotherapy prolonged survival in younger adult patients with acute myeloid leukemia and a FLT3 mutation, according to a randomized trial.

Adding Ublituximab to Ibrutinib Improves Relapsed CLL Response Rates

News | June 23, 2017 | Leukemia & Lymphoma, Hematologic Malignancies

By Dave Levitan

Adding the novel CD20 inhibitor ublituximab to ibrutinib offered improved response rates and greater depth of response over ibrutinib alone in patients with relapsed/refractory chronic lymphocytic leukemia.

Immunotherapy Safely Treats Advanced Squamous Cell Carcinoma

News | June 23, 2017 | Skin Cancer (Nonmelanoma)

By Mark L. Fuerst

An anti–PD-1 monoclonal antibody is safe and effective for patients with unresectable, locally advanced, or metastatic cutaneous squamous cell carcinoma.

NSAID Use After Diagnosis Improved CRC Survival in KRAS Wild-Type Patients

News | June 22, 2017 | Colorectal Cancer, Gastrointestinal Cancer

By Leah Lawrence

Long-term survivors of wild-type KRAS colorectal cancer tumors had significantly improved survival with regular use of nonsteroidal anti-inflammatory drugs.